Emergent BioSolutions Is Buying PaxVax For $270m


Emergent BioSolutions, Inc., a $560.8m specialty pharmaceutical company focused on public health threats,  is buying PaxVax, Inc., a PE- backed company focuses on specialty vaccines against existing and emerging infectious diseases. The deal expands Emergent's specialty vaccine platform. PaxVax's main product include Vivotif, the only oral vaccine licensed by FDA to prevent typhoid fever, and Vaxhora, a vaccine against cholera developed for the U.S. Department of Defense. FDA granted PaxVax Fast Track designation for its vaccine to the Chikungunya virus in May 2018. The virus spreads through mosquito bites and can cause large outbreaks, which have occurred in Africa, Asia, Europe, and the Indian and Pacific Oceans. Symptoms include fever, joint pain, headache, muscle pain, joint swelling, or rash. Emergent will also take over PaxVax’ European-based cGMP biologics manufacturing facilities and about 250 staffers. Deal value - $270m.



Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare mergers